Interesting articles / presentations
Global BioPharmaceutical Royalty Rates & Deal Terms Survey
The 25 most influential people in biopharma today – 2013
Valuation Analysis in Pharmaceutical Licensing and M&A Transactions
Rebuilding Big Pharma’s Business Model
Clinical Development Success Rates 2006-2015
Corporate Finance
Equity Valuation: Models from Leading Investment Banks
Discounted Cash Flow Valuation
Regression Analysis in Valuation Engagements
Biotech / Pharma Reports
Beyond Borders – Matters of Evidence
PhRMA Pharmaceutical Industry Profile
Global life sciences outlook Optimism tempered by reality in a “new normal”
The Pharmaceutical Industry in Figures
The Global Use of Medicines: Outlook through 2016
Venture Capital, Private Equity & Hedge Funds
Global Healthcare Private Equity Report 2016
VC Deal Terms: Double-Dipping in the Life Sciences
Guide on Private Equity and Venture Capital for Entrepreneurs
What Do Venture Capitalists Really Do, and Where Do They Learn to Do It?
Pharma / Biotech Valuation
Which parameters are inconveniently uncertain?
The valuation of part-developed projects in the pharmaceutical sector
The Cost of Capital for Early-Stage Biotechnology Ventures
Discount rates for Biotech companies
Discount rates in drug development
Should we discount by project or by company?
Should we discount by project or by company? (continued)
Pharma & Biotech Development and Valuation
Real-Options Valuation for a Biotechnology Company
Application of real options analysis for pharmaceutical R&D project valuation
M&A
Pharma / Biotech M&A
HBM Pharma/Biotech M&A Report 2017
Global M&A Report Pharma/Biotech 2016
ii) General M&A
A simple M&A model for all seasons
Addressing corruption risk in M&A transactions
Comprehensive M&A due diligence checklist for buyers
How M&A can grow portfolio value
M&A: Using uncertainty to your advantage
Deal or no deal: Can busted M&A deals be avoided?
Academic articles
Mergers and Acquisitions in the Pharmaceutical and Biotech Industries
Proactive Versus Reactive M&A Activities in the Biotechnology Industry
How to improve R&D productivity: the pharmaceutical industry’s grand challenge
Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances